Skip to main content
OpenTrials
Completed

NCT Number: NCT03351218

Agency in Dystonia

In this study, using computerized cognitive assessments combined with multi-modal neuroimaging approach investigators aim to address three specific questions on patients with cervical and myoclonus dystonia:

(i) investigate various aspects of the sense of agency and relationship to the severity of dystonia symptoms, (ii) characterize the possible link between abnormalities of movement perception and alteration of sense of agency in dystonia, (iii) (identify the neuronal underpinnings of the defective sense of agency in dystonia.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Dystonia, Primary Central Nervous System Diseases Dystonic Disorders Movement Disorders Nervous System Diseases

Age range

15 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Centre d'investigation Clinique

Paris, Île-de-France Region, 75013, France

About this study

This is a single-centre, two-group ( dystonia and control), case-control study using behavioural and novel multimodal neuroimaging techniques to address the study aims.

The battery of the tasks will include explicit-agency tasks, a visual discrimination task on objects movement perception. The magnetic resonance acquisition protocol will include MP2RAGE structural (10 min duration), multi echo (3 echo times) multiband (MB factor 4) resting state functional neuroimaging (15 minutes duration) and multi shell diffusion imaging sequence (15 minutes duration)

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • diagnosis of isolated adult-onset cervical dystonia (CD) or myoclonus dystonia (MD);
  • duration of disease of more than one year
  • no botulinum toxin injection for at least three months before the study
  • normal or corrected-to-normal vision.

Exclusion criteria

  • any neurological history except for dystonia,
  • history of dopamine antagonist treatment,
  • secondary dystonia,
  • dystonia in the upper limbs,
  • inability to maintain gaze straight.

Treatment and study plan

Behavioral testing - computerized tasks

Behavioral

Cognitive behavioral testing and cerebral MRI

Primary outcomes

  1. agency tasks behavioral outcome measures

    Time frame: throughout study completion, an average 2 years

    response time

  2. agency tasks behavioral outcome measures

    Time frame: throughout study completion, an average 2 years

    response accuracy in tasks trials

Secondary outcomes

  1. MRI measures

    Time frame: throughout study completion, an average 2 years

    cortical thickness

  2. MRI measures

    Time frame: throughout study completion, an average 2 years

    basal ganglia volume

Sponsors and collaborators

Lead sponsor

Institut National de la Santé Et de la Recherche Médicale, France

Other Gov

Registry information

Official study title

Neuronal Correlates of Agency in Dystonia

Acronym: AGENT10

Important dates

Study start
2017
Primary completion
2020
Study completion
2022
First posted
Nov 22, 2017
Registry last updated
Dec 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.